Survival Outcome and Optimal Candidates of Primary Tumor Resection for Patients With Metastatic Medullary Thyroid Cancer
Authors' conclusion
PTR may confer therapeutic benefits for carefully selected individuals with metastatic MTCs. To integrate these insights into clinical decision-making settings, it is imperative to undertake multicenter prospective studies in the future.
Study context
- Population
- Patients initially diagnosed with metastatic medullary thyroid cancer (MTC), SEER database, 2010–2020
- Participants
- 186 patients
- Exposure
- Primary tumor resection (PTR) vs no PTR
- PTRn = 105
- Outcome
- Overall and cancer-specific mortality with PTR
Methodological detailspopulation-based, SEER database, multivariable Cox regression
- Population-based
- SEER database
- Multivariable Cox regression
Main finding
As reported in the abstract
PTR
56.45%
105
All P < .05
Observational data: associations, not effects.
Further findings
Brain metastasis and survival
- Significantly worse overall survival with brain metastasis
- P = 0.007
- Significantly worse cancer-specific survival with brain metastasis
- P = 0.0013
PTR by metastatic pattern (bone, lung, liver or distant lymph node)
- PTR significantly lowered risk of overall and cancer-specific mortality
- all P < .05
PTR in patients with 1 or 2 metastases
- Favorable overall survival with surgical resection
- P = 0.008
- Favorable cancer-specific survival with surgical resection
- P = 0.0247
Original publication
Survival Outcome and Optimal Candidates of Primary Tumor Resection for Patients With Metastatic Medullary Thyroid Cancer. J Clin Endocrinol Metab. Published 4 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →